CRISPR THERAPEUTICS AG (CRSP) Stock Analyst Earnings Estimates
NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.2M -99.87% | 371.206M 30,833.83% | 37.314M -89.95% | 47.877M 28.31% | 176.21M 268.05% | 410.76M 133.11% | 886.73M 115.88% | 2.284B 157.58% | 6.102B 167.16% | 1.355B -77.79% | 1.706B 25.90% | |
| EBITDA YoY % growth | -649M -265.77% | -202.701M 68.77% | -447.307M -120.67% | -507.764M -13.52% | -468.327M 7.77% | -517.737M -10.55% | -12.817M 97.52% | 258.36M 2,115.71% | 728.28M 181.89% | 1.214B 66.69% | 1.693B 39.46% | |
| EBIT YoY % growth | -673.2M -280.24% | -222.538M 66.94% | -466.566M -109.66% | -535.577M -14.79% | -444.838M 16.94% | -352.569M 20.74% | -2.089M 99.41% | 605.24M 29,071.85% | 292.6M -51.66% | 456.29M 55.94% | 588.82M 29.05% | |
| Operating Margin | -56,100.00% | -59.95% | -1,250.38% | -1,118.65% | -252.45% | -85.83% | -0.24% | 26.50% | 4.80% | 33.67% | 34.51% | |
| EPS YoY % growth | -8.37 -289.37% | -1.96 76.58% | -4.37 -122.96% | -5.53 -26.45% | -4.56 17.51% | -3.55 22.11% | 0.23 106.48% | 6.54 2,740.78% | 25.11 284.14% | 3.86 -84.62% | 5.08 31.56% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.45 2.45% | -1.39 -37.25% | -1.25 -183.15% | -1.20 24.08% | -1.11 23.71% | -1.05 24.52% | -0.97 21.75% |
| Revenue Q2Q % growth | 6.38M 1,134.04% | 12.833M 2,031.73% | 23.781M -33.37% | 19.83M 2,192.49% | 39.435M 518.10% | 45.129M 251.66% | 48.003M 101.85% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -135.298M 10.55% | -126.403M -14.78% | -119.565M -85.12% | -123.505M 16.79% | -122.595M 9.39% | -122.396M 3.17% | -125.041M -4.58% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -1.58 -10.49% | -1.28 | -0.30 | -23.86% |
| Q4 2024 Q2Q % growth | -0.44 -140.00% | -1.19 | 0.75 | 63.08% |
| Q3 2024 Q2Q % growth | -1.01 28.37% | -1.45 | 0.44 | 30.41% |
| Q2 2024 Q2Q % growth | -1.49 -52.04% | -1.55 | 0.06 | 4.06% |
| Q1 2024 Q2Q % growth | -1.43 -113.43% | -1.36 | -0.07 | -5.19% |
| Q4 2023 Q2Q % growth | 1.10 178.01% | -0.07 | 1.17 | 1,593.05% |
| Q3 2023 Q2Q % growth | -1.41 37.05% | -1.99 | 0.58 | 29.13% |
| Q2 2023 Q2Q % growth | -0.98 59.17% | -2.16 | 1.18 | 54.63% |
| Q1 2023 Q2Q % growth | -0.67 71.12% | -1.74 | 1.07 | 61.43% |
| Q4 2022 Q2Q % growth | -1.41 23.37% | -2.35 | 0.94 | 39.87% |
| Q3 2022 Q2Q % growth | -2.24 -34.13% | -2.34 | 0.10 | 4.11% |
| Q2 2022 Q2Q % growth | -2.40 -125.42% | -2.27 | -0.13 | -5.64% |
| Q1 2022 Q2Q % growth | -2.32 -53.64% | -1.98 | -0.34 | -17.46% |
| Q4 2021 Q2Q % growth | -1.84 -22.67% | -1.80 | -0.04 | -1.98% |
| Q3 2021 Q2Q % growth | -1.67 -26.52% | -1.79 | 0.12 | 6.77% |
| Q2 2021 Q2Q % growth | 9.44 826.15% | 3.59 | 5.85 | 162.72% |
| Q1 2021 Q2Q % growth | -1.51 -31.30% | -1.50 | -0.01 | -0.53% |
| Q4 2020 Q2Q % growth | -1.50 -394.12% | -1.30 | -0.20 | -15.52% |
| Q3 2020 Q2Q % growth | -1.32 -155.00% | -1.21 | -0.11 | -9.22% |
| Q2 2020 Q2Q % growth | -1.30 -28.71% | -0.97 | -0.33 | -34.71% |
| Q1 2020 Q2Q % growth | -1.15 -23.66% | -1.07 | -0.08 | -7.34% |
| Q4 2019 Q2Q % growth | 0.51 | -0.64 | 1.15 | 179.88% |
| Q3 2019 Q2Q % growth | 2.40 | -0.97 | 3.37 | 348.11% |
| Q2 2019 Q2Q % growth | -1.01 | -0.92 | -0.09 | -10.27% |
| Q1 2019 Q2Q % growth | -0.93 | -0.90 | -0.03 | -3.20% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | 865K 71.63% | 6.628M | -5.763M | -86.95% |
| Q4 2024 Q2Q % growth | 35.691M -82.26% | 8.044M | 27.647M | 343.70% |
| Q3 2024 Q2Q % growth | 602K | 6.944M | -6.342M | -91.33% |
| Q2 2024 Q2Q % growth | 517K -99.26% | 3.609M | -3.092M | -85.67% |
| Q1 2024 Q2Q % growth | 504K -99.50% | 27.076M | -26.572M | -98.14% |
| Q4 2023 Q2Q % growth | 201.206M | 134.27M | 66.936M | 49.85% |
| Q3 2023 Q2Q % growth | -100.00% | 8.117M | -8.117M | -100.00% |
| Q2 2023 Q2Q % growth | 70M 34,900.00% | 1.742M | 68.258M | 3,918.37% |
| Q1 2023 Q2Q % growth | 100M 11,011.11% | 23.44M | 76.56M | 326.62% |
| Q4 2022 Q2Q % growth | -100.00% | 7.265M | -7.265M | -100.00% |
| Q3 2022 Q2Q % growth | 100K -87.50% | 1.649M | -1.549M | -93.94% |
| Q2 2022 Q2Q % growth | 200K -99.98% | 2.105M | -1.905M | -90.50% |
| Q1 2022 Q2Q % growth | 900K 80.00% | 2.82M | -1.92M | -68.09% |
| Q4 2021 Q2Q % growth | 12.9M 3,125.00% | 2.318M | 10.582M | 456.51% |
| Q3 2021 Q2Q % growth | 800K 700.00% | 1.145M | -345K | -30.13% |
| Q2 2021 Q2Q % growth | 900.7M | 429.34M | 471.36M | 109.79% |
| Q1 2021 Q2Q % growth | 500K 150.00% | 1.159M | -659K | -56.86% |
| Q4 2020 Q2Q % growth | 400K -99.48% | 2.372M | -1.972M | -83.14% |
| Q3 2020 Q2Q % growth | 100K -99.95% | 2.066M | -1.966M | -95.16% |
| Q2 2020 Q2Q % growth | -100.00% | 18.488M | -18.488M | -100.00% |
| Q1 2020 Q2Q % growth | 200K -33.33% | 3.103M | -2.903M | -93.55% |
| Q4 2019 Q2Q % growth | 77M | 36.543M | 40.457M | 110.71% |
| Q3 2019 Q2Q % growth | 211.9M | 6.279M | 205.621M | 3,274.74% |
| Q2 2019 Q2Q % growth | 300K | 4.016M | -3.716M | -92.53% |
| Q1 2019 Q2Q % growth | 300K | 1.785M | -1.485M | -83.19% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 2.76% | -13.96% | -0.06% | -9.81% |
| Revenue | -4.33% | -30.35% | -1.49% | -15.22% |